Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Fitbit launches lower-cost fitness devices to combat Samsung, Apple

Fitbit launched the company’s cheapest smartwatch to defend its position as the second-largest seller of smartwatches after Apple.

Read More »

U.S. top court rejects Maryland bid to revive drug price-gouging law

The U.S. Supreme Court rejected Maryland’s bid to revive a law aimed at preventing price gouging by pharmaceutical companies, dealing a setback to the power of states to rein in prescription drug costs.

Read More »

Sanofi and Regeneron cutting list price of cholesterol drug by 60 percent

Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.

Read More »

J&J to add prices to television ads

Johnson & Johnson will start adding the price of the company’s medicines to television commercials by March 2019, becoming the first drugmaker to heed a call by U.S. President Donald Trump.

Read More »

FDA approves cheaper Botox rival to treat frown lines

An injection to treat forehead wrinkles is set to rival Allergan plc’s Botox after U.S. regulators approved Evolus Inc.’s cheaper treatment, sending the Newport Beach, Calif.-based company’s shares up about 5 percent.

Read More »

AstraZeneca Lays off 210 in Colorado

AstraZeneca filed a Worker Readjustment and Retraining Notification Act (WARN) notice with the State of Colorado, indicating plans to lay off 210 people in Boulder and Longmont.

Read More »

J&J raises U.S. prices on around two dozen drugs

Johnson & Johnson raised U.S. prices on around two dozen prescription drugs, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among the company’s top-selling products.

Read More »

Drug companies greet 2019 with U.S. price hikes

Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world’s top-selling medicine Humira, although the pace of price hikes was slower than during 2018.

Read More »

Alexion wins early U.S. approval for rare blood disorder drug

The U.S. Food and Drug Administration approved Alexion Pharmaceuticals Inc.’s rare blood disorder drug Ultomiris, an early backing that also solidifies the company’s dominant market position.

Read More »

At Least 16 Generic Drug Companies and 300 Drugs Target of Price-Fixing Investigation

In 2016, 20 state attorneys general filed a federal lawsuit alleging that six generic drug makers artificially inflated and manipulated prices for an antibiotic and an oral diabetes drug. The goal was to reduce competition. According to The Washington Post, the investigation has spread out to include price-fixing by at least 16 companies and 300 drugs.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom